Related Experiment Video

Updated: Jun 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Castration-resistant prostate cancer: targeted therapies and individualized treatment

Rahul Aggarwal1, Charles J Ryan

  • 1Department of Medicine, University of California, San Francisco, CA 94143-1270, USA. Rahul.Aggarwal@ucsf.edu

The Oncologist
|February 23, 2011
PubMed

Insights

Castration-resistant prostate cancer (CRPC) treatment faces challenges due to tumor heterogeneity. Personalized medicine using genomic and proteomic analyses aims to improve targeted therapy efficacy for CRPC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hormone-sensitive prostate cancer progresses to castration-resistant prostate cancer (CRPC) through various molecular mechanisms.
  • Novel targeted agents for CRPC inhibit androgen receptor (AR)-mediated signaling or non-AR pathways.
  • Variable efficacy of current CRPC treatments is attributed to the biologic heterogeneity of the disease.

Purpose of the Study:

  • To investigate an individualized treatment approach for CRPC based on molecular profiling.
  • To determine if matching treatments to specific molecular subtypes of CRPC can improve patient outcomes.
  • To explore the potential of genomic and proteomic analyses in guiding CRPC therapy.

Main Methods:

  • Review of molecular mechanisms driving CRPC progression.
  • Analysis of targeted agents inhibiting AR-mediated and non-AR-mediated signaling pathways.
  • Investigation of genomic and proteomic analyses for tumor subtyping.

Main Results:

  • CRPC exhibits significant biologic heterogeneity, impacting treatment efficacy.
  • Targeted agents show variable efficacy, necessitating refined treatment strategies.
  • Individualized treatment based on molecular subtypes is under investigation.

Conclusions:

  • Personalized medicine approaches, utilizing genomic and proteomic data, hold promise for improving CRPC treatment.
  • Identifying molecular subtypes can lead to more effective targeted therapy selection.
  • Insights from CRPC research may inform therapeutic development for other solid tumors.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...